Photocure Reports Flat Q3 2026 Revenues of NOK 134.2 Million
Photocure ASA recorded stable third-quarter revenues for its Cysview/Hexvix diagnostic product, matching the previous year's performance of NOK 134.2 million.
Oslo-based medical technology firm Photocure ASA posted third-quarter 2026 revenues of NOK 134.2 million, showing negligible change from the NOK 134.1 million reported during the same period in 2025. Adjusted EBITDA for the quarter stood at NOK 18.5 million, a slight decrease from the NOK 18.9 million recorded a year prior.
The company’s primary revenue driver remains its blue-light cystoscopy product, marketed as Hexvix in Europe and Cysview in the United States. The product is used to improve the detection of bladder cancer during surgical procedures.
While the financial results indicate steady adoption of the technology, the company continues to navigate a competitive diagnostic oncology market. Photocure management has provided updated expectations for the full year 2026 as it monitors sales trajectories across its core markets.